Keywords: Canada, Drug review process, Cancer drugs, Cost-effectiveness, pCODR

New pan-Canadian cancer drug review process gets underway

Article | 14 July 2011

Cancer patients and clinicians in Canadians are set to benefit from the implementation of the pan-Canadian Oncology Drug Review (pCODR), ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in